Protein C News and Research

RSS

Researchers develop guidelines for assessment, treatment and management of lymphedema

Lymphedema, a chronic swelling condition that can appear after breast cancer surgery, is a risk for 1.3 million breast cancer survivors. Although lymphedema can cause lifelong swelling in the arms, back, neck and chest, there is no national standard of diagnosis or care.

18 Feb 2010

Neuroimaging study may lead to new therapeutic treatments for stroke and hearing loss

Duke University Medical Center scientists crowded around a laser-powered microscope in a darkened room to peer into the brain of an anesthetized juvenile songbird right after he heard an adult tutors' song for the first time.

18 Feb 2010

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.

18 Feb 2010

New research units established for Japanese-German research collaboration

With its ten new Research Units, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is intensifying interdisciplinary and multiple-location collaboration among researchers pursuing specific scientific questions and new avenues of research.

17 Feb 2010

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

Talecris Biotherapeutics announced today that it has received approval from Health Canada for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more purified and concentrated version of PROLASTIN® produced using advances in manufacturing technology. A similar approval for PROLASTIN-C was granted by the U.S. Food and Drug Administration on October 17, 2009.

17 Feb 2010

Menopause supplement to bring body back into balance

Whitemark Homes, Inc., is pleased to announce a satisfaction guaranteed top selling product line by Ribbon Naturals Corp., complete system Menopause Solutions. A solution for women who are dissatisfied with the results they receive from common, everyday menopause supplements. Now there is a supplement for menopause that brings the body back into balance.

17 Feb 2010

Eleven Biotherapeutics announces completion of $35M Series A funding

Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, announced today it has completed a $35 million Series A financing co-led by Flagship Ventures and Third Rock Ventures. Proceeds from the financing will be used to build the research and development and business development teams for Eleven Biotherapeutics, in addition to advancing the company’s portfolio of engineered proteins through clinical proof of concept.

17 Feb 2010

Researchers discover new strategy to overcome drug resistance in breast cancer

Combining tamoxifen, the world's most prescribed breast cancer agent, with a compound found in the flowering plant feverfew may prevent initial or future resistance to the drug, say researchers at Georgetown Lombardi Comprehensive Cancer Center.

17 Feb 2010

Simple urine tests for four proteins may detect early kidney disease in people with lupus

Simple urine tests for four proteins might be able to detect early kidney disease in people with lupus, researchers at UT Southwestern Medical Center have found in an animal study.

17 Feb 2010

Protein crucial in mediating anti-inflammatory actions of nuclear lipid receptors discovered

Researchers at the Swedish medical university Karolinska Institutet have discovered a protein that is crucial in mediating the anti-inflammatory actions of nuclear lipid receptors. The findings, published in the research journal Genes & Development, link lipid metabolism and inflammation and open up new possibilities for developing treatments of metabolic diseases associated with inflammation, such as diabetes and atherosclerosis.

17 Feb 2010

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

CalciMedica today announced that the US Patent and Trademark Office has issued to CalciMedica US Patent No. 7,645,588, a composition patent involving STIM1, a key component of the calcium release-activated calcium (CRAC) channel. The patent, entitled "Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use," has a priority date of March 4, 2003 and was issued on January 12, 2010.

17 Feb 2010

FDA approves risk management program on ESA's for treating anemia due to chemotherapy

The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs). For patients with cancer, the program is also designed to help ensure the appropriate administration of these drugs, which they receive to treat anemia that can occur as a result of chemotherapy.

17 Feb 2010

Iowa State University researchers awarded 30 ARRA grants worth $16.38M

Iowa State University researchers have so far won 30 grants worth a total $16.38 million from federal agencies awarding money from the American Recovery and Reinvestment Act (ARRA).

17 Feb 2010

Researchers have traced protein that stops cells from becoming cancerous

In the dominoes that make up human cells, researchers at the University of Michigan Comprehensive Cancer Center have traced another step of the process that stops cells from becoming cancerous.

17 Feb 2010

TKS4 protein plays significant role in Frank-Ter Haar syndrome

An international team of investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham, formerly Burnham Institute for Medical Research), Nijmegen Centre for Molecular Life Sciences and other organizations have discovered that TKS4, a protein implicated in cancer metastasis, also plays a significant role in Frank-Ter Haar syndrome (FTHS), a rare fatal disorder.

17 Feb 2010

Adding daclizumab to standard treatment reduces enlarged brain lesions in patients with relapsing MS

An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.

17 Feb 2010

Researchers use model organism to test new therapies for retinal degeneration

Research by Johns Hopkins sensory biologists studying fruit flies, has revealed a critical step in fly vision. Humans with problems in this same step suffer retinal dystrophies, which manifest as visual defects ranging from mild visual impairments to complete blindness.

16 Feb 2010

AB SCIEX acquires liquid chromatography business of Eksigent Technologies

AB SCIEX, a global leader in life science analytical technologies, today announced that it has acquired the liquid chromatography business of Eksigent Technologies. This acquisition significantly strengthens AB SCIEX’s position in liquid chromatography, which is a key technology used frequently in a broad range of life science applications such as protein biomarker research, drug discovery and basic research.

16 Feb 2010

Narcolepsy is indeed an autoimmune disorder, finds University of Lausanne study

Individuals with the sleep disorder narcolepsy suffer with excessive daytime sleepiness and attacks of muscle paralysis triggered by strong emotions (a condition known as cataplexy).

16 Feb 2010

TB's mechanism to evade body's immune system identified

Indiana University School of Medicine researchers have identified a mechanism used by the tuberculosis bacterium to evade the body's immune system and have identified a compound that blocks the bacterium's ability to survive in the host, which could lead to new drugs to treat tuberculosis.

16 Feb 2010

Protein C News and Research

Researchers develop guidelines for assessment, treatment and management of lymphedema

Neuroimaging study may lead to new therapeutic treatments for stroke and hearing loss

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

New research units established for Japanese-German research collaboration

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

Menopause supplement to bring body back into balance

Eleven Biotherapeutics announces completion of $35M Series A funding

Researchers discover new strategy to overcome drug resistance in breast cancer

Simple urine tests for four proteins may detect early kidney disease in people with lupus

Protein crucial in mediating anti-inflammatory actions of nuclear lipid receptors discovered

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

FDA approves risk management program on ESA's for treating anemia due to chemotherapy

Iowa State University researchers awarded 30 ARRA grants worth $16.38M

Researchers have traced protein that stops cells from becoming cancerous

TKS4 protein plays significant role in Frank-Ter Haar syndrome

Adding daclizumab to standard treatment reduces enlarged brain lesions in patients with relapsing MS

Researchers use model organism to test new therapies for retinal degeneration

AB SCIEX acquires liquid chromatography business of Eksigent Technologies

Narcolepsy is indeed an autoimmune disorder, finds University of Lausanne study

TB's mechanism to evade body's immune system identified

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News